



MINISTERIO  
DE SANIDAD, SERVICIOS SOCIALES  
E IGUALDAD



agencia española de  
medicamentos y  
productos sanitarios

DEPARTAMENTO DE  
MEDICAMENTOS  
VETERINARIOS

***FLUVEX 50 mg/ml solution for  
injection for cattle, pigs and horses***

**Company:**

**SP VETERINARIA S.A**

**VARIATION ASSESSMENT REPORT**

**Variation procedure application N° ES/V/0133/001/IB/002**

CORREO ELECTRÓNICO

[mresvet@aemps.es](mailto:mresvet@aemps.es)

FLUVEX 50 mg/ml solution for injection for cattle, pigs and horses  
ES/V/0133/001/IB/002

C/ CAMPEZO, 1 – EDIFICIO 8  
28022 MADRID  
TEL: 91 822 54 01  
FAX: 91 822 5443



## VARIATION ASSESSMENT REPORT

### PRODUCT DETAILS

Name of product	FLUVEX 50 mg/ml solution for injection for cattle, pigs and horses
Active ingredient(s)	Flunixin meglumine
Target Species	Cattle, horses and pigs
Route of administration	Solution for injection Cattle and horses: intravenous use Pigs: Intramuscular use

### APPLICATION DETAILS

Type of Application	Type IB
Name and Address of Applicant	SP VETERINARIA SA Ctra Reus Vinyols km 4.1 Riudoms (43330) Spain
Phone and Fax Numbers	Telephone number: +34977768867 Fax number (optional): +34977850405
Email address	M Victòria Gironès E-mail: <a href="mailto:vgirones@spveterinaria.com">vgirones@spveterinaria.com</a>
Reference Number for Application	ES/V/0133/001/IB/002
Reference Number in RMS	1755 ESP
Date of the first marketing authorisation in RMS	29-June- 2007

### REFERENCE MEMBER STATE DETAILS

Assessment Report prepared by	ES
Date of preparation	14/05/2015
Contact name	M <sup>a</sup> Carmen Sánchez Martínez
Address	AEMPS C/ Campezo, nº 1, bl.8, 1E 28022 Madrid Spain
Phone number	+ 34 91 822 5414
Fax number	+ 34 91 822 5443
Email for Applicants	<a href="mailto:mresvet@agemed.es">mresvet@agemed.es</a>
Email for CMSs	<a href="mailto:es-v.mrve@msc.es">es-v.mrve@msc.es</a>

### CONTACT WITH ASSESORS

Area	Contact name	Telephone number	E-mail address
Safety	Amparo López Ribera	+34 91 8225410	<a href="mailto:alopezri@aemps.es">alopezri@aemps.es</a>
Efficacy	Raul Belmar Liberato	+34 91 8225420	<a href="mailto:rbelmar@aemps.es">rbelmar@aemps.es</a>

## **NATURE OF VARIATION**

**C.I.2.a) Change (s) in the Summary of product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medical products following assessment of the same change for the reference product. Implementation of change(s) for which no new additional data is required to be submitted by the MAH (Type IB variation).**

<b>Current situation</b>	<b>Proposed changes</b>
SPC authorized after MRP	SPC updated according to SPC of the reference product in Spain.

## **SUMMARY OF THE DOSSIER**

For commercial reasons the applicant has considered that it is necessary to update part IB (SPC and PIL texts) according to reference product in Spain. Subsequently of this change a type IB variation is submitted:

- **C.I.2.a) Change (s) in the Summary of product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medical products following assessment of the same change for the reference product. Implementation of change(s) for which no new additional data is required to be submitted by the MAH**

For this purpose the applicant has submitted the following documents to support the update of the SPC and PIL texts

- Track changes and clean versions of the proposed SPC and PIL texts which have been updated according to SPC and PIL texts of the reference product in Spain.

### RMS comments

*The above variation is considered acceptable on the basis that the application has been submitted simultaneously to all Concerned Member States, the relevant fees have been paid as required by national competent authorities and correct supporting information and documents have also been presented according to the conditions specified for the proposed changes as listed in the Commission Guideline. Failure to comply with this provision may subsequently deem the variations invalid. Consequently, the Spanish Agency (AEMPS) can accept the variation detailed in the application.*